|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions

News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia


Company Profiles

Research Store

Research Events
Post an Event

Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
T2 Biosystems Announces Issuance of Patents Covering T2MR Direct Detection Technology
11/14/2012 10:38:29 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the U.S. Patent and Trademark Office has issued two patents adding depth and breadth to the Company’s intellectual property portfolio. These patents cover both the device and methods related to the Company’s flagship T2Candida assay and the detection of additional biological analytes, including specific drug and biomarker targets, in biological samples using the T2MR platform. “These patents illustrate the success that T2 Biosystems’ team has had in its mission to create breakthrough diagnostic detection technology that will enable the first direct detection of analytes in biological samples,” said John McDonough, President and CEO, T2 Biosystems. “Direct detection provides many advantages, including industry-leading clinical performance and the ability to run molecular, immuno and hemostasis assays on a single platform. This intellectual property covers the proprietary methods for our lead product, the T2Candida assay. Importantly, though, it extends the coverage to additional key aspects of our T2MR-based platform: detection of multiple analytes associated with disease, therapeutic management and monitoring a patient’s response to medical intervention.”
|
|
|
|
|
|
|
|
|
|
|